Harrow (HROW) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for June 18, 2025, at the corporate office in Nashville, TN, with all stockholders invited to attend and vote on key proposals.
Proxy materials are available online, with options for electronic or paper delivery, and voting can be done in person, by mail, phone, or internet.
Record date for voting is April 21, 2025, with 36,685,171 shares outstanding and a quorum requirement of a majority of shares.
Voting matters and shareholder proposals
Election of four directors to serve until the 2026 Annual Meeting.
Approval of the 2025 Incentive Stock and Awards Plan, enabling 3,950,000 new shares for equity-based awards.
Ratification of Crowe LLP as the independent registered public accounting firm for 2025.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes, with the Board recommending annual votes.
Stockholders may submit proposals for the 2026 Annual Meeting by December 30, 2025, and recommend director nominees per bylaw requirements.
Board of directors and corporate governance
Board reduced to four members after a resignation; three are independent, and one is CEO.
Committees include Audit, Compensation, and Nomination and Corporate Governance, all composed of independent directors.
Lead Independent Director role established to ensure independent oversight when CEO is also Chairman.
Board and committees met regularly in 2024, with 100% attendance by directors.
Latest events from Harrow
- Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 202610 Mar 2026 - Record 36% revenue growth in 2025 sets up $350M–$365M guidance and strong momentum for 2026.HROW
Q4 20253 Mar 2026 - Q2 2024 revenue up 46% on IHEEZO and VEVYE growth; strong outlook for 2024.HROW
Q2 20242 Feb 2026 - Rapid revenue growth and new product launches position the company for strong future expansion.HROW
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - VEVYE, IHEEZO, and Triessence drive growth toward a $1B revenue target by 2027.HROW
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 44–46% year-over-year, with strong product launches and robust outlook.HROW
Q3 202414 Jan 2026 - Prescription innovation and targeted launches drive growth, with MELT-300 as a major future catalyst.HROW
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Record revenue, margin gains, and strong outlook fueled by branded product growth.HROW
Q4 202426 Dec 2025 - Melt acquisition and product innovation drive growth, with biosimilars set to expand retina market reach.HROW
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025